A Single DNA Letter Tweak Rewires a Cancer Gene’s Translation and Stress Response

Deep inside the genome, a change of just one DNA letter can quietly decide how much of a tumor-suppressing protein a cell makes. That is the striking conclusion of a new study published in the journal iScience, in which researchers in Italy and France traced a common inherited variant in the 3′ untranslated region of the DDIT4 gene and showed that it controls how efficiently the gene’s messenger RNA is translated into protein. The finding adds a compelling new dimension to the genetics of cancer: variants that do not change the protein’s amino acid sequence, nor even the amount of mRNA a gene produces, but instead act at the level of translation itself.

The research team, led by scientists at the University of Trento, set out to hunt for what they call tranSNPs, single-nucleotide polymorphisms that create allele-specific differences in translation efficiency. Their method is elegant in its logic. In a cell that is heterozygous at a given SNP, two versions of the same mRNA coexist, distinguishable only by that single letter. If both alleles are translated equally, they should appear in the same proportion in the pool of total RNA and in the pool of RNA bound to polysomes, the ribosome assemblies where protein synthesis happens. When the allelic fractions diverge between the two compartments, it signals that one allele is being translated more efficiently than the other.

Using RNA-sequencing data from HCT116 colon cancer cells, both untreated and treated with nutlin, a drug that activates the tumor suppressor p53 without damaging DNA, the team identified 40 candidate tranSNPs, roughly 7 percent of the SNPs they could analyze. Twenty-one of these sat in 3′ UTRs, the regulatory tail regions of mRNAs that are increasingly recognized as hotspots for post-transcriptional control. The researchers validated three candidates using orthogonal approaches, including Sanger sequencing of polysomal and total RNA fractions, targeted re-sequencing, and luciferase reporter assays in which the variant-containing UTR fragments were cloned downstream of a reporter gene.

One variant stood out: rs1053639, a T/A polymorphism in the 3′ UTR of DDIT4, also known as REDD1 or RTP801. DDIT4 is a negative regulator of mTORC1, the master growth-promoting kinase complex, and is an established target of p53, RFX7, and ATF4. It is widely regarded as a tumor suppressor. The rs1053639 variant is relatively common in the human population, making its functional consequences potentially far-reaching. To prove causality rather than mere correlation, the team used CRISPR-Cas9 genome editing to generate isogenic HCT116 cell clones homozygous for either the T or the A allele, along with the parental heterozygous line, creating a clean experimental trio.

The results were unambiguous. Cells homozygous for the T allele produced significantly more DDIT4 protein than A-allele cells, both at baseline and, even more strikingly, under stress. When cells were challenged with thapsigargin, a drug that induces endoplasmic reticulum stress and strongly induces DDIT4 transcription, the protein gap between genotypes widened. The same pattern held when p53 was activated by nutlin: TT clones mounted a robust DDIT4 protein response, while AA clones showed little induction. Crucially, the difference could not be explained by mRNA levels, mRNA stability, protein half-life, alternative splicing, or the antisense transcript DDIT4-AS1. The variant was acting on translation.

Polysome profiling revealed the mechanism in finer detail. After thapsigargin treatment, DDIT4 mRNA in TT cells shifted into heavier polysomal fractions, indicating more active translation, while no such shift occurred in AA cells. Reporter assays confirmed that as little as 109 nucleotides of the DDIT4 3′ UTR surrounding the SNP were sufficient to confer allele-specific differences in protein output, and the effect reproduced in unrelated cell lines including A549 lung cancer cells and non-transformed RPE-1 cells, arguing that the phenomenon is not an artifact of the edited clones.

The search for the trans-acting factor led to RBMX, an RNA-binding protein predicted to bind the T allele preferentially. RNA electrophoretic mobility shift assays with recombinant RBMX and structured RNA probes, designed using multiple RNA-folding prediction algorithms, supported a possible preference for the T allele, and AlphaFold 3 modeling suggested the T-allele probe sits in a more favorable conformation for binding. RNA immunoprecipitation in the edited cells confirmed preferential RBMX binding to the T allele, particularly in the cytoplasm. Because RBMX is mainly nuclear, the team examined mRNA localization and found that DDIT4 mRNA was significantly more cytoplasmic in TT cells and more nuclear in AA cells. When RBMX was depleted with siRNAs, DDIT4 protein levels in TT clones dropped to AA-clone levels, and the number of perinuclear DDIT4 mRNA granules rose, consistent with mRNA being trapped in an export or storage state rather than being translated.

Downstream, the consequences rippled through the mTOR pathway. In response to thapsigargin or nutlin, TT clones showed a significant reduction in the phosphorylation of eIF4EBP1 and S6K, canonical readouts of mTORC1 activity, while AA clones did not. TT cells also exhibited higher autophagic flux under chloroquine treatment. Global translation and proliferation in standard culture were similar between genotypes, but the picture changed under competitive conditions. In co-culture experiments where fluorescently labeled TT and AA cells competed over fifteen days, AA cells progressively gained the upper hand, an advantage that vanished when RBMX was silenced. The same AA advantage appeared in xenograft experiments in transparent Casper zebrafish embryos, where A-allele cells grew faster both when co-injected with T-allele cells and when transplanted alone.

The clinical implications are tantalizing. TT clones were significantly more resistant to niclosamide, nutlin, and thapsigargin than AA clones, suggesting that genotype could shape drug response. Interrogating The Cancer Genome Atlas, the researchers found that colorectal cancer patients homozygous for the A allele had a worse disease-free interval than those carrying at least one T allele, under a recessive model. The team also established that an immunohistochemistry protocol can distinguish DDIT4 protein levels by genotype, opening a path toward translating the finding into pathology practice. The authors caution that these prognostic analyses are exploratory and require validation in independent cohorts.

Beyond cancer, the study delivers a methodological gift. By comparing allelic fractions between total and polysomal RNA across biological replicates, the tranSNP pipeline offers a general framework for discovering inherited variants that act on translation, a layer of genetic regulation that genome-wide association studies have largely overlooked. Given that DDIT4 also features in liver disease, neurodegeneration, pulmonary injury, and retinopathy, and that mTOR signaling sits at the heart of cellular metabolism, a single common DNA letter that tunes this gene’s translational output may echo well beyond the tumor. The work suggests that the human genome’s quietest variations, the ones that change not what genes say but how loudly they are heard by the ribosome, may deserve far more attention in the quest to understand individual differences in disease risk and treatment response.

Subject of Research: A germline 3′ UTR variant regulating allele-specific translation of the DDIT4 stress-response gene in cancer cells

Article Title: A common germline 3′ UTR variant controls DDIT4 translation efficiency and stress responses in cancer cells

Article References: Hamadou, M. H., Alunno, L., Venturelli, T., Valentini, S., Dalfovo, D., Lorenzini, F., Mattivi, A., Vigorito, V., Grupelli, G. P., Matte’, A., Gatto, P., Pancher, M., Valentini, C., De Sanctis, V., Bertorelli, R., Marcel, V., Cusanelli, E., Freddi, S., Bertalot, G., … Inga, A. (2026). A common germline 3′ UTR variant controls DDIT4 translation efficiency and stress responses in cancer cells. iScience, 29(11), Article 117707. https://doi.org/10.1016/j.isci.2026.117707

Image Credits: AI Generated

DOI: 10.1016/j.isci.2026.117707

Keywords: DDIT4, tranSNPs, translation efficiency, 3′ UTR, mTORC1, p53, RBMX, polysome profiling, CRISPR-Cas9, cancer genetics, endoplasmic reticulum stress, TCGA